ClinicalTrials.gg
TerminatedNCT01445938Updated Dec 13, 2012

Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria

A Phase 2 interventional study of SAR97276A and arthemeter + lumefantrine (ACTs) in Malaria, sponsored by Sanofi. Terminated at 4 sites in 4 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2012-12-13.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Data Monitoring Committee recommendation

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Malaria by Sanofi — none open to participants now, none under way, none of them phase 3. Malaria · Sanofi.

Enrollment
11th of 11
20 · median 366
Started
2011
the only one that year
Phase 2
2 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Malaria by Sanofi, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 2 in phase 2, and was the 11th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

None of the 11 studies in Malaria by Sanofi is open now. The open studies under Malaria, anywhere →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Malaria by Sanofi as a file.
02

Study summary

Primary Objective:

To assess the antiparasitic activity of intramuscular (IM) SAR97276A based on parasite reduction ratio at 72 hours in pediatric patients with uncomplicated malaria

Secondary Objectives:

  • To assess the evolution of clinical signs and symptoms (including the need for a rescue therapy) in pediatric patients with uncomplicated malaria receiving SAR97276A with reference to Artemisinin-Based Combination Therapy (ACTs)
  • To assess the pharmacokinetics profile of SAR97276A in pediatric patients with uncomplicated malaria
  • To assess the safety profile of SAR97276A in pediatric patients with uncomplicated malaria
  • To assess the pharmacokinetic-pharmacodynamic relationship of SAR97276A
Read the detailed description

The total duration per patients will last approximately 28 ± 2 days broken down as follows:

  • A screening phase up to 12-hours
  • A 28 ± 2 days study period
03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with symptomatic infection by Plasmodium falciparum microscopically confirmed in blood smear at Day-1 visit
  • Fever (tympanic or rectal temperature ≥ 38 C) or documented history of fever within the last 24h
  • Asexual parasitemia of ≥ 2 000 parasites/μL in blood smear at D-1 visit
  • Signed Form by the parents or legal guardian
  • Age: 12 to 17 years old for step 1
  • Age: 2 to 11 years old for step 2 and step 3

Exclusion criteria

Exclusion criteria:

  • Participation in another clinical trial within the last 3 months or participation within a different cohort in this PDY11737 clinical trial or participation to previous trial with SAR97276
  • Documented history of adequate treatment with antimalarials expected to be effective within the preceding 72 hours
  • Severe concomitant disease (including concomitant febrile illnesses or infection)
  • Any sign suggestive of severe malaria
  • Severe malnutrition
  • Asexual parasitemia: Plasmodium falciparum > 100,000 parasites/μL in blood smear at D-1 visit
  • Previous treatment within 3 weeks prior to inclusion, and concomitant treatment with potent inhibitors or CYP3A4 inducers or CYP2D6 substrates or potent CYP2D6 inhibitors
  • Known serious adverse event reaction or to Artemisinin-Based Combination Therapy (ACTs) or any from the positive control therapy (Artemisinin Combined Treatments) or warning/precaution of use as defined in the respective National Product Labeling
  • Pregnant or breast-feeding women
  • Women of not protected by effective method of birth control, or not willing to use an effective contraceptive(s) method(s) for the duration of the study (e.g.: double barrier method), and/or who are unwilling or unable to be tested for pregnancy,
  • CPK above 3 ,
  • Underlying hepatobiliary disease or >3 ULN.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Step 1 (SAR97276A od)

    1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days

    Drug: SAR97276A

  • Experimental
    Step 1 (SAR97276A bid)

    1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days

    Drug: SAR97276A

  • Active comparator
    Step 1 (ACTs)

    1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days

    Drug: arthemeter + lumefantrine (ACTs)

  • Experimental
    Step 2 (SAR97276A)

    1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)

    Drug: SAR97276A

  • Active comparator
    Step 2 (ACTs)

    1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days

    Drug: arthemeter + lumefantrine (ACTs)

  • Experimental
    Step 3 (SAR97276A)

    1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)

    Drug: SAR97276A

Interventions

  • DrugSAR97276A

    Pharmaceutical form:solution for injection Route of administration: intramuscular

  • Drugarthemeter + lumefantrine (ACTs)

    Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Parasite Reduction Ratio (PRR)

    Time frame: at 72 hours

Secondary outcomes

  1. Evolution of mean Parasitaemia over time (nb/µL)

    Time frame: every 6 hours from baseline up to 72 hours (day 4)

  2. Evolution of mean Gametocytes count over time (nb/µL)

    Time frame: from baseline to end of study (day 28 ± 2)

  3. Fever Clearance (time to reach Temperature < 38°C)

    Time frame: every 6 hours from baseline up to 72 hours (day 4)

  4. General conditions improvement: mean total symptom score over time

    Time frame: every 6 hours from baseline up to 72 hours (day 4)

  5. SAR97276 pharmacokinetic profile in plasma and blood

    Time frame: from baseline up to 12 hours after the last study drug intake on (Day 3

07

Study locations

4 sites
  • Investigational Site Number 204001
    Cotonou, Benin
  • Investigational Site Number 854001
    Ouagadougou, Burkina Faso
  • Investigational Site Number 266001
    Libreville, Gabon
  • Investigational Site Number 404001
    Kisumu, Kenya
08

References and documents

Publications

  • Held J, Supan C, Salazar CLO, Tinto H, Bonkian LN, Nahum A, Sie A, Abdulla S, Cantalloube C, Djeriou E, Bouyou-Akotet M, Ogutu B, Mordmuller B, Kreidenweiss A, Siribie M, Sirima SB, Kremsner PG. Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients. Malar J. 2017 May 4;16(1):188. doi: 10.1186/s12936-017-1832-x. PubMed 28472957 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2011
First posted
Oct 4, 2011
Start
Oct 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Dec 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01445938
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 4, 2011
Start date
Oct 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Dec 13, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion